GSK to pay $20M to SEC to resolve bribery charges

U.K. pharmaceutical giant GlaxoSmithKline will pay a civil money penalty in the amount of $20 million to the Securities and Exchange Commission to resolve charges concerning bribery payments made to government officials in China. Jaclyn Jaeger reports.

THIS IS MEMBERS-ONLY CONTENT

Already a Member? SIGN IN here. If you’re not, click HERE for more information on our 30-day free trials and why you’re not able to view this story.